2022
Sick leave duration as a potential marker of functionality and disease severity in depression
VOLZ, H. P., Eliška BARTEČKŮ, Lucie BARTOVA, J. BESSA, D. DE BERARDIS et. al.Základní údaje
Originální název
Sick leave duration as a potential marker of functionality and disease severity in depression
Autoři
VOLZ, H. P. (garant), Eliška BARTEČKŮ (203 Česká republika, domácí), Lucie BARTOVA (203 Česká republika), J. BESSA, D. DE BERARDIS, J. DRAGASEK, H. KOZHUHAROV, M. LADEA, J. LAZÁRY, M. ROCA, G. USOV, A. WICHNIAK, B. GODMAN a S. KASPER
Vydání
International Journal of Psychiatry in Clinical Practice, Oxon, TAYLOR & FRANCIS LTD, 2022, 1365-1501
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30215 Psychiatry
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.000
Kód RIV
RIV/00216224:14110/22:00126851
Organizační jednotka
Lékařská fakulta
UT WoS
000777522800001
Klíčová slova anglicky
Absenteeism; depression; functionality; major depressive disorder; return to work; sick leave
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 16. 1. 2023 13:57, Mgr. Tereza Miškechová
Anotace
V originále
Objective: To discuss the impact of depression on work and how depression-related sick leave duration could be a potential indicator and outcome for measuring functionality in depression. Methods: Our review was based on a literature search and expert opinion that emerged during a virtual meeting of European psychiatrists that was convened to discuss this topic. Results: Current evidence demonstrates that depression-related sick leave duration is influenced by multiple disease-, patient- and work-related factors, together with societal attitudes towards depression and socioeconomic conditions. A wide variety of pharmacological and non-pharmacological treatments and work-based interventions are effective in reducing depression-related sick leave duration and/or facilitating return to work. Recent real-world evidence showed that patients treated with antidepressant monotherapy appear to recover their working life faster than those receiving combination therapy. Although depression-related sick leave duration was found to correlate with severity of depressive symptoms, it cannot be used alone as a viable marker for disease severity. Conclusions: Given its multifactorial nature, depression-related sick leave duration is not on its own a viable outcome measure of depression severity but could be used as a secondary outcome alongside more formal severity measures and may also represent a useful measure of functionality in depression.